No Data
No Data
Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement
Arovella Therapeutics (ASX:ALA) reached an agreement with Teva Pharmaceuticals to conclude their obligations under the ZolpiMist insomnia treatment product license and supply deal, according to a Thur
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%
Arovella Therapeutics (ASX:ALA) completed the process development work for its patent-protected manufacturing process necessary for large-scale good manufacturing practice (GMP) manufacturing of its A
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise
Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors to raise about AU$12.5 million via a placement of 125 million new fully paid ordinary share
While Shareholders of Arovella Therapeutics (ASX:ALA) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%
Arovella Therapeutics (ASX:ALA) said its collaboration with Imugene (ASX:IMU) to combine ALA‐101 and onCARlytics has ended, effective immediately, according to a Wednesday filing with the Australian S
Arovella Boosts Solid Tumor Pipeline With Novel CAR-iNKT Cell Armouring Tech License
Arovella Therapeutics (ASX:ALA) secured an exclusive license from the University of North Carolina Lineberger Comprehensive Cancer Center to integrate cytokine technology into its CAR-iNKT cell platfo
No Data